Impact of missing data due to dropouts on estimates of the treatment effect in a randomized trial of antiretroviral therapy for HIV-infected individuals

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology

Volumn 12, Issue 1, 1996, Pages 46-55

  Raboud, J M ^a,b   Montaner, J S G ^a,b,c   Thorne, A ^b   Singer, J ^a,b   Schechter, M T ^a,b,c   Rachlis, A ^d   Gill, J ^d   Beaulieu, R ^d   Tsoukas, C ^d   Fanning, M ^d   Cameron, W ^d   Lalonde, R ^d   Bergeron, M ^d   Schlech, W ^d   Salit, I ^d   Phillips, P ^d   Salomon, H ^d   Spira, B ^d   Conway, B ^d   Auclair, C ^d   Cassol, S ^d   O'Shaughnessy, M V ^d   Wainberg, M A ^d   more..

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b Canadian HIV Trials Network   (Canada)

^c ST PAUL S HOSPITAL   (Canada)

^d NONE

Author keywords

CD4 lymphocyte count; Missing data; Nonrandom dropout; Randomized trial

Indexed keywords

DIDANOSINE; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 1842614350     PISSN: 10779450     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-199605010-00007     Document Type: Article

References (21)

1. Brown MB. A test for the difference between two treatments in a continuous measure of outcome when there are dropouts. Controlled Clin Trials 1992;13:213-25.
2. Diggle P, Kenward MG. Informative dropout in longitudinal studies. Appl Stat 1994;43:49-93.
3. Gillings D, Koch G. The application of the principle of intention-to-treat to the analysis of clinical trials. Drug Information J 1991;25:411-24.
4. Gould AL. A new approach to the analysis of clinical drug trials with withdrawals. Biometrics 1980;36:721-7.
5. Greenlees JS, Reece WS, Zieschang KD. Imputation of missing values when the probability of response depends on the variable being imputed. J Am Stat Assoc 1982;77:251-61.
6. Heyting A, Tolboom JTBM, Essers JGA. Statistical handling of dropouts in longitudinal clinical trials. Stat Med 1992;11:2043-61.
7. Little JA, Rubin DB. Statistical analysis with missing data. New York: Wiley, 1987.
8. Laird NM. Missing data in longitudinal studies. Stat Med 1988;7:305-15.
9. Wu MC, Bailey K. Analysing changes in the presence of informative right censoring caused by death and withdrawal. Stat Med 1988;7:337-46.
10. Wu MC, Carroll RJ. Estimation and comparison of changes in the presence of informative right censoring by modelling the censoring process. Biometrics 1988;44:175-88.
11. Wu MC, Bailey K. Estimation and comparison of changes in the presence of informative right censoring: conditional linear model. Biometrics 1989;45:939-55.
12. Fischl MA, Olson RM, Follansbee SE, et al. Zalcitabine compared with zidovudine in participants with advanced HIV-1 infection who received previous zidovudine therapy. Ann Intern Med 1993;118:762-9.
13. Hamilton JD, Hartigan PM, Simberkoff MS, et al. A controlled trial of early versus late treatment with zidovudine in symptomatic human immunodeficiency virus infection. Results of the Veterans Affairs Cooperative Study. N Engl J Med 1992;326:437-43.
14. Kahn JO, Lagakos SW, Richman DD, et al. A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. The NIAID AIDS Clinical Trials Group. N Engl J Med 1992;327:581-7.
15. Spruance SL, Pavia AT, Peterson D, et al. Didanosine compared with continuation of zidovudine in HIV-infected participants with signs of clinical deterioration while receiving zidovudine. Ann Intern Med 1994;120:360-8.
16. Volberding PA, Lagakos SW, Koch MA, et al. Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. N Engl J Med 1990;322: 941-9.
17. Montaner JSG, Wainberg M, Rachlis A, et al. A double blind comparative trial of didanosine versus continued zidovudine therapy for moderately advanced human immunodeficiency virus infection. Ann Intern Med 1995;123:561-71.
18. Cox DR. Regression models and life tables. J R Soc Stat 1972;34:187-202.
19. Liang KY, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika 1986;73:13-22.
20. + lymphocytes are an incomplete surrogate marker for clinical progression in persons with asymptomatic HIV infection taking zidovudine. Ann Intern Med 1993;118:674-80.
21. Fleming TR. Surrogate markers in AIDS and cancer trials. Stat Med 1994;13:1423-35.